Key result
Intravenous clevidipine produced a dose-dependent reduction in blood pressure with short half-lives (2.2 and 16.8 min) and an ED50 of approximately 1.5 microg/kg/min in hypertensive patients.
Why the study?
Does intravenous clevidipine reduce blood pressure and demonstrate favorable pharmacokinetics compared to placebo in patients with mild to moderate hypertension?
Population
20 patients with mild to moderate hypertension
Comparison
Clevidipine intravenously at target dose rates… vs Placebo
Design
RCT, Randomized to clevidipine or placebo; each patient received in random…
Authors
Loading...
Supports titratable BP control in hypertension; confirms dose-dependent efficacy and rapid offset in RCT.
RCT (n=20)
randomized
Does intravenous clevidipine reduce blood pressure and demonstrate favorable pharmacokinetics compared to placebo in patients with mild to moderate hypertension?
Intravenous clevidipine provides rapid, dose-dependent blood pressure reduction with a very short half-life, making it suitable for precise and rapid blood pressure control.
Schwieler et al. (1999) conducted an RCT in mild to moderate hypertension (n=20). clevidipine vs. placebo was evaluated on pharmacokinetics, dose-effect and blood concentration-effect relations, and tolerability. Intravenous clevidipine produced a dose-dependent reduction in blood pressure with short half-lives (2.2 and 16.8 min) and an ED50 of approximately 1.5 microg/kg/min in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: